U.S. government expands assistance to J&J COVID-19 vaccine research

By The Science Advisory Board staff writers

November 16, 2020 -- The Biomedical Advanced Research and Development Authority (BARDA) is expanding its partnership with Johnson & Johnson by providing additional support for the ongoing development of its investigational COVID-19 vaccine candidate.

Under the amendment to the initial agreement, Janssen will commit approximately $604 million and BARDA will commit approximately $454 million to support the ongoing phase III Ensemble clinical trial evaluating the investigational COVID-19 vaccine candidate as a single-dose in up to 60,000 volunteers worldwide.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.